Stock listing
OTC:VAXX Vaxxinity, Inc. Stock
Follow Vaxxinity, Inc. into a list and get an email when it puts out news.
Share price · OTC:VAXX
$0.0001 USD 0.0000 (0.0%)
Close on Nov 17, 2026
- Day range
- $0.0001 – $0.0275 USDNov 17, 2026
- Volume
- 318 sharesNov 17, 2026
- Market cap
- —Left out: price × shares is far from the company's reported size

Daily closes
Last 3 months, Oct 26, 2026 – Nov 17, 2026 · OTC:VAXX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.0001 | 0.0000 | 0.0% | $0.0275 | $0.0275 | $0.0001 | 318 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0205 | $0.0001 | 1,502 | |
| $0.0001 | -0.0009 | -90.0% | $0.0010 | $0.0010 | $0.0001 | 1,312 | |
| $0.0010 | 0.0000 | 0.0% | $0.0010 | $0.0010 | $0.0010 | 219 | |
| $0.0010 | -0.0140 | -93.3% | $0.0010 | $0.0010 | $0.0010 | 219 | |
| $0.0150 | -0.0100 | -40.0% | $0.0150 | $0.0150 | $0.0150 | 230 | |
| $0.0250 | +0.0110 | +78.6% | $0.0250 | $0.0250 | $0.0250 | 251 | |
| $0.0140 | -0.0010 | -6.7% | $0.0140 | $0.0140 | $0.0140 | 213 | |
| $0.0150 | 0.0000 | 0.0% | $0.0150 | $0.0150 | $0.0150 | 212 | |
| $0.0150 | 0.0000 | 0.0% | $0.0150 | $0.0150 | $0.0150 | 212 | |
| $0.0150 | -0.0120 | -44.4% | $0.0150 | $0.0150 | $0.0150 | 212 | |
| $0.0270 | +0.0085 | +45.9% | $0.0210 | $0.0270 | $0.0210 | 489 | |
| $0.0185 | -0.0090 | -32.7% | $0.0185 | $0.0185 | $0.0185 | 215 | |
| $0.0275 | — | — | $0.0275 | $0.0275 | $0.0275 | 215 |
- Ticker
- OTC:VAXX
- Asset type
- Stock
- Exchange
- OTC
- Currency
- USD
Latest news
Vaxxinity, Inc. on 6ix
- News releases
- 7 in all · newest Dec 12, 2023 · oldest 2023
Valuation
price Nov 17, 2026
- Enterprise value
- No market cap
- P/E
- No market cap
- EV/sales
- No market cap
- EV/EBITDA
- No market cap
- Price/book
- No market cap
- Gross margin
- No statements on 6ix yet
- Operating margin
- No statements on 6ix yet
- Net margin
- No statements on 6ix yet
- Debt to equity
- No statements on 6ix yet
- Beta vs S&P 500
- 0.73
Team and board
| Officer | Role |
|---|---|
| Mei Mei Hu | Chief Executive Officer |
Events
| Quarter | Results |
|---|---|
| Quarter to Sep 30, 2025 | Nov 28, 2025 |
| Quarter to Jun 30, 2025 | Aug 29, 2025 |
| Quarter to Mar 31, 2025 | Apr 1, 2025 |
| Quarter to Sep 30, 2024 | Nov 29, 2024 |
| Quarter to Jun 30, 2024 | Aug 8, 2024 |
| Q1 2024 | May 7, 2024 |
| Q4 2023 | Mar 27, 2024 · After close |
| Q3 2023 | Nov 8, 2023 · Before open |
| Q2 2023 | Aug 9, 2023 · Before open |
| Q1 2023 | May 9, 2023 · Before open |
All 19 quarters
| Quarter | Results |
|---|---|
| Q4 2022 | Mar 27, 2023 · Before open |
| Q3 2022 | Nov 10, 2022 · Before open |
| Q2 2022 | Aug 11, 2022 · Before open |
| Q1 2022 | May 9, 2022 · Before open |
| Q4 2021 | Mar 24, 2022 · After close |
| Q3 2021 | Dec 23, 2021 · After close |
| Q2 2021 | Sep 30, 2021 |
| Q1 2021 | Jun 30, 2021 |
| Q4 2020 | Mar 31, 2021 |
Financials
Annual, in USD
Income statement
| Line | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | 0 | -1.00K | 66.0K | 557.0K | 0 |
| Cost of revenue | 2.23M | 1.68M | 1.94M | 52.0K | 107.0K |
| Gross profit | -2.23M | -1.68M | -1.87M | 505.0K | -107.0K |
| Research and development | 33.7M | 47.6M | 71.4M | 20.6M | 10.7M |
| Selling, general and administrative | 22.4M | 28.4M | 51.8M | 12.2M | 3.00M |
| Operating income | -58.3M | -76.0M | -125.1M | -32.3M | -13.7M |
| Depreciation and amortization | 2.23M | 1.68M | 1.10M | 717.0K | 107.0K |
| EBITDA | -56.1M | -74.3M | -124.0M | -31.6M | -13.6M |
| Interest expense | 696.0K | 514.0K | 840.0K | 1.18M | 435.0K |
| Income before tax | -56.9K | -75.2M | -137.2M | -40.0M | -14.2M |
| Income tax | -56.9K | -12.0K | 840.0K | -4.58M | 56.0K |
| Net income | -56.9K | -75.2M | -137.2M | -40.0M | -14.2M |
| Earnings per share, basic | -0.00 | -0.60 | -1.09 | -0.32 | -0.11 |
Balance sheet
| Line | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Cash and equivalents | 4.93M | 33.5M | 144.9M | 31.1M | 476.0K |
| Short-term investments | 25.5M | 53.4M | 869.0K | 10.0K | |
| Receivables | 414.0K | 414.0K | 393.0K | 387.0K | 303.0K |
| Inventory | 6.12M | 8.51M | 3.31M | ||
| Current assets | 33.2M | 93.9M | 154.1M | 35.7M | 1.44M |
| Property, plant and equipment | 12.5M | 12.2M | 12.2M | 160.0K | |
| Total assets | 44.3M | 106.4M | 166.7M | 50.1M | 1.59M |
| Accounts payable | 1.78M | 5.29M | 3.19M | 9.02M | 1.28M |
| Current liabilities | 17.6M | 30.9M | 27.5M | 37.2M | 19.9M |
| Long-term debt | 13.3M | 9.93M | 10.3M | 10.7M | 1.12M |
| Total debt | 15.2M | 14.5M | 10.7M | 38.3M | 14.3M |
| Total liabilities | 30.9M | 44.2M | 38.1M | 137.5M | 50.1M |
| Shareholders' equity | 13.4M | 62.2M | 128.6M | -87.4M | -48.5M |
| Shares outstanding | 126.5M | 125.9M | 125.4M | 125.5M | 125.5M |
Cash flow
| Line | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Cash from operations | -57.2M | -55.9M | -81.0M | -33.9M | -12.3M |
| Capital spending | -803.0K | -1.87M | -1.32M | -1.48M | -1.48M |
| Free cash flow | -58.0M | -57.8M | -82.3M | -35.4M | -12.3M |
| Cash from investing | 28.8M | -54.4M | -1.32M | -1.48M | -1.48M |
| Cash from financing | -1.14M | -167.0K | 196.2M | 66.1M | 11.1M |
| Dividends paid | -59.8M | ||||
| Share buybacks | 263.0K | 59.9M | -41.0K | 0 | |
| Change in cash | -29.5M | -110.5M | 113.9M | 30.7M | -1.13M |
Cap table
Built by 6ix from Vaxxinity, Inc.’s releases
- Common shares
- 112,910,552
- Fully diluted
- 112,910,552
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 112,910,552 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 112,910,552 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Peter Diamandis Other companies: Celularity Inc. (Director · Since at least Jul 16, 2021); DPCM Capital Inc (Director · Oct 20, 2020 – Aug 5, 2022 · Past); CuriosityStream Inc. (Director · Nov 19, 2019 – Nov 19, 2019 · Past) | Director · Nov 10, 2021 – Jun 20, 2023 · Past |
| Farshad Guirakhoo Other companies: GeoVax Labs, Inc. (Chief Scientific Officer · Oct 19, 2015 – Dec 17, 2018 · Past) | Chief Scientific Officer · Nov 10, 2021 – May 3, 2022 · Past |
| George R Hornig Other companies: Healthwell Acquisition Corp I (Director · Aug 2, 2021 – Aug 2, 2021 · Past) | Director · Jan 3, 2022 – Jun 20, 2023 · Past |
| Katherine A Eade Other companies: Harvard Bioscience, Inc. (Director · Since at least Oct 24, 2017) | Director · Feb 1, 2023 – Jun 20, 2023 · Past |
| James Alan Smith | Director · Feb 1, 2023 – Jun 20, 2023 · Past |
| Lou Reese | See Remarks, Director · Nov 10, 2021 – Mar 7, 2023 · Past |
| Martin Doran | See Remarks · Nov 10, 2021 – Nov 10, 2021 · Past |
| Mei Mei Hu | Chief Executive Officer · Since at least Nov 5, 2026 |
| Peter Powchik | Director · Mar 31, 2022 – Oct 1, 2023 · Past |
Log in to ask 6ix AI your own questions about Vaxxinity, Inc.